Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Abrisqueta P, Sancho J, Cordoba R, Persky D, Andreadis C, Huntington S, Carpio C, Giles D, Wei X, Li Y, Zuraek M, Burgess M, Hege K, Martín A. Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood 2019, 134: 4089. DOI: 10.1182/blood-2019-125310.Peer-Reviewed Original ResearchIndependent data monitoring committeeCommon adverse eventsDose-limiting toxicityAdverse eventsCD47 antibodyData monitoring committeeSpeakers bureauR NHLFrequent grade 3/4 adverse eventsInternational Working Group response criteriaGrade 3/4 adverse eventsCelgene CorporationRefractory non-Hodgkin lymphomaBCR-ABL kinase domainAdvisory CommitteeMonitoring committeeF. Hoffmann-La Roche LtdDisease control ratePrior systemic therapyTreatment-related deathsDurable complete responseGrade 3 thrombocytopeniaInfusion-related reactionsModest clinical activityDose-limiting thrombocytopeniaPhysician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.Peer-Reviewed Original ResearchConceptsRituximab discontinuationRituximab initiationHodgkin's lymphomaRelative riskPhysician experienceHigh-quality cancer careOlder adultsInitiation of rituximabEarly treatment discontinuationInfusion-related reactionsPopulation-based studySEER-Medicare dataNon-Hodgkin lymphomaModified Poisson regressionCancer treatment outcomesEarly discontinuationTreatment discontinuationAnticancer immunotherapyPhysician volumeCancer careImproved outcomesOncologists' experiencesTreatment outcomesDiscontinuationRituximab